The FDA has authorized Abbott’s Libre Duo — the first wearable in the US to continuously monitor ketones, and the first in the world to track both ketones and blood sugar in a single device.
Announced August 25, 2026, the device is cleared for people aged 2 and older living with diabetes. A small skin-worn sensor measures glucose and ketone levels in the fluid just under the skin every minute over a 10-day wear period, sending readings wirelessly to a compatible smartphone.
An early-warning system for DKA
The standout feature is ketone tracking. When the body runs low on insulin, ketones can rise to dangerous levels and trigger diabetic ketoacidosis (DKA) — a life-threatening emergency. Libre Duo can send automatic alerts when ketones approach a concerning threshold, potentially helping patients and caregivers act before DKA develops. Authorization was supported by six clinical studies enrolling more than 600 participants, evaluating the accuracy of both the glucose and ketone functions.
Why it matters
Continuous glucose monitors have transformed diabetes care, but ketones — a key warning sign of DKA — have typically required separate finger-stick or blood tests. Folding continuous ketone monitoring into a familiar wearable could give people with diabetes, especially those on insulin, an earlier and easier way to catch a dangerous complication.